Linked Life Data

10646901

Source:http://linkedlifedata.com/resource/pubmed/id/10646901

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2000-2-4
pubmed:databankReference
pubmed:abstractText
The expression of the BCL-2 family proteins, BCL-2, BAX, BCL(XL) and BAK have been determined in a panel of 12 human ovarian carcinoma cell lines encompassing a wide range in sensitivity to cisplatin. Whereas BAX, BCL(XL) and BAK levels did not correlate with sensitivity, there was a statistically significant inverse correlation (r = -0.81; P = 0.002) between growth inhibition by cisplatin and BCL-2 levels. In sublines possessing acquired resistance to various platinum-based drugs or across a panel of human ovarian carcinoma xenografts, there was no consistent pattern of BCL-2 expression. Two relatively sensitive lines (A2780 and CH1) have been stably transfected with bcl-2 and bcl(XL) respectively and two relatively resistant lines (A2780cisR and SKOV-3) stably transfected with bax. Overexpression of BCL-2 in A2780 cells led to resistance to cisplatin compared to the vector control when assayed at 48 h post-drug incubation but a significant increase in sensitivity at 96 h. Relative rates of apoptosis at 48- and 96-h post-cisplatin exposure mirrored the growth inhibition. There was no significant difference in sensitivity of the pair of lines by clonogenic assay. No significant changes in chemosensitivity to a variety of DNA-damaging or tubulin-interactive agents were observed in the remaining transfected lines. Taken together, these results suggest that, in human ovarian carcinoma cells, high BCL-2 levels (either naturally occurring or through gene transfection) confers a trend towards sensitivity not resistance to platinum drugs.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/10646901-1586979, http://linkedlifedata.com/resource/pubmed/commentcorrection/10646901-1617660, http://linkedlifedata.com/resource/pubmed/commentcorrection/10646901-1854622, http://linkedlifedata.com/resource/pubmed/commentcorrection/10646901-7478541, http://linkedlifedata.com/resource/pubmed/commentcorrection/10646901-7585531, http://linkedlifedata.com/resource/pubmed/commentcorrection/10646901-8427780, http://linkedlifedata.com/resource/pubmed/commentcorrection/10646901-8599870, http://linkedlifedata.com/resource/pubmed/commentcorrection/10646901-8616869, http://linkedlifedata.com/resource/pubmed/commentcorrection/10646901-8752171, http://linkedlifedata.com/resource/pubmed/commentcorrection/10646901-9472630, http://linkedlifedata.com/resource/pubmed/commentcorrection/10646901-9584207
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0007-0920
pubmed:author
pubmed:issnType
Print
pubmed:volume
82
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
436-40
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
2000
pubmed:articleTitle
BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma.
pubmed:affiliation
CRC Centre for Cancer Therapeutics, Institute of Cancer Research, Belmont, Sutton, UK.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't